Targeted nanoparticles reduce tumor scarring and enable immunotherapy response in mice
Many liver and lung cancers arise in tissue that's already been scarred by chronic disease, such as hepatitis, cirrhosis or long-term lung damage. That scarring creates an environment that suppresses nearby immune cells, so by the time a tumor takes hold, it's often already shielded from the immune...
Image: Phys.org
Many liver and lung cancers arise in tissue that's already been scarred by chronic disease, such as hepatitis, cirrhosis or long-term lung damage. That scarring creates an environment that suppresses nearby immune cells, so by the time a tumor takes hold, it's often already shielded from the immune system and immunotherapy.
Originally published at Phys.org
